European journal of medical research, Год журнала: 2025, Номер 30(1)
Опубликована: Май 20, 2025
Язык: Английский
The Lancet Regional Health - Europe, Год журнала: 2024, Номер 44, С. 100977 - 100977
Опубликована: Авг. 23, 2024
SummaryMultiple sclerosis is a chronic, inflammatory, and neurodegenerative disease of the central nervous system major cause neurological disability in young adults. Its prevalence incidence are increasing, it has been estimated at over 2.8 million cases worldwide, addition to recent trends towards shift MS older ages, with peak estimates sixth decade life. Although historically relapsing progressive phases have considered separate clinical entities, evidence progression independent relapse activity (PIRA) led reconsideration multiple as continuum, which features variably coexist from earliest stages disease, challenging traditional view course. In this Series article, we provide an overview how description course epidemiological Europe evolved. For purpose, focus on concept PIRA, discussing its potential main mechanism by patients acquire disability, definition varies between studies, ongoing research field. We emphasise importance incorporating assessment hidden manifestations into patient management help uncover quantify PIRA phenomenon possible implications for future changes classification disease. At same time, insights overcoming challenges identifying defining adopting new understanding MS.
Язык: Английский
Процитировано
27
Annals of Neurology, Год журнала: 2024, Номер 96(5), С. 826 - 845
Опубликована: Июль 25, 2024
Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition "progression independent relapsing activity." We propose concept smouldering-associated-worsening (SAW), encompassing physical and cognitive symptoms, resulting from smouldering pathological processes, remain unmet targets. provide a consensus-based framework possible substrates manifestations MS, we discuss clinical, radiological, serum/cerebrospinal fluid biomarkers for potentially monitoring SAW. Finally, share considerations optimizing disease surveillance implications clinical trials to promote integration MS into routine practice future research efforts. ANN NEUROL 2024;96:826-845.
Язык: Английский
Процитировано
20
Neurology, Год журнала: 2025, Номер 104(4)
Опубликована: Янв. 23, 2025
Although multiple sclerosis (MS) can be conceptualized as a network disorder, brain analyses typically require advanced MRI sequences not commonly acquired in clinical practice. Using conventional MRI, we assessed cross-sectional and longitudinal structural disconnection morphometric similarity networks people with MS (pwMS), along their relationship disability. In this monocentric study, 3T of pwMS healthy controls (HC) was retrospectively analyzed. Physical cognitive disabilities were the expanded disability status scale (EDSS) symbol digit modalities test (SDMT), respectively. Demyelinating lesions automatically segmented, corresponding masks used to assess pairwise between atlas-defined regions based on normative tractography data. Morphometric Inverse Divergence method, computed cortical FreeSurfer surface reconstruction. network-based statistics (NBS) its extension NBS-predict, tested whether subject-level connectomes associated disease status, progression, disability, long-term confirmed progression (CDP), independently from global lesion burden atrophy. We studied 461 (age = 37.2 ± 10.6 years, F/M 324/137), 1,235 visits (mean follow-up time 1.9 2.0 range 0.1-13.3 years), 55 HC 42.4 15.7 years; 25/30). Long-term available for 285 12.4 2.8 127 whom (44.6%) exhibited CDP. At baseline, mostly centered around thalami sensory association hubs, while extensively disrupted (pFWE < 0.01). EDSS related frontothalamic 0.01) left perisylvian cortex 0.02), SDMT cortico-subcortical hemisphere Longitudinally, both disruption significantly progressed 0.04 pFWE 0.01), correlating increase (ρ 0.07, p 0.02 ρ 0.11, 0.001), baseline predicted CDP (accuracy 59% [58-60], 0.03). Structural networks, through are sensitive MS-related damage progression. They explain disease-related predict evolution atrophy, potentially adding established measures biomarkers severity
Язык: Английский
Процитировано
2
Nature Medicine, Год журнала: 2024, Номер 30(10), С. 3015 - 3026
Опубликована: Авг. 15, 2024
Язык: Английский
Процитировано
16
Expert Review of Neurotherapeutics, Год журнала: 2024, Номер 24(2), С. 201 - 216
Опубликована: Янв. 18, 2024
Introduction While magnetic resonance imaging (MRI) is established in diagnosing and monitoring disease activity multiple sclerosis (MS), its utility predicting progression less clear.
Язык: Английский
Процитировано
11
Multiple Sclerosis Journal, Год журнала: 2025, Номер unknown
Опубликована: Фев. 25, 2025
Background: Treatment with cladribine tablets (CladT) in relapsing–remitting multiple sclerosis (RRMS) reduced global grey matter (GM) atrophy, but the effects on regional GM are unknown. Objectives: This study aimed to investigate effect of CladT compared placebo magnetic resonance imaging (MRI)-derived patterns atrophy. Methods: We used MRI and clinical data from CLARITY study, including 393 people RRMS (CladT (3.5 mg/kg), n = 200 or placebo, 193) at baseline, 24, 48 96 weeks after treatment initiation. SynthSeg-derived volume changes atrophy derived source-based morphometry were analysed for group differences over time associations disability using mixed-effect models. Results: Deep (β −0.03, p < 0.01), thalamus −0.04, 0.01) brainstem–thalamus pattern 0.05) showed higher reduction treated group. These regions no during a predefined pseudo-atrophy period, where loss was worse Between W24 W96, Expanded Disability Status Scale (EDSS) scores associated lower deep −0.16, 0.001), thalamic −0.12, 0.05). Conclusion: clinically relevant slower neurodegeneration RRMS. Strongest seen GM, thalamus, brainstem, underlining importance measures assessing effects.
Язык: Английский
Процитировано
1
NeuroSci, Год журнала: 2022, Номер 3(4), С. 667 - 676
Опубликована: Ноя. 22, 2022
Cognitive impairment (CI) is a core feature of multiple sclerosis (MS) and affects up to 65% patients in every phase the disease, having deep impact on all aspects patients' lives. functions most frequently involved include information processing speed, learning memory, visuospatial abilities, executive function. The precise pathogenetic mechanisms underpinning CI MS are still largely unknown, but deemed be mainly related pathological changes lesioned normal-appearing white matter, specific neuronal grey matter structures, immunological alterations, with particular synaptic transmission plasticity. Moreover, much research needed therapeutic strategies. Small moderate efficacy has been reported for disease-modifying therapies, particularly high-efficacy drugs, symptomatic therapies (dalfampridine), while strongest benefit emerged after cognitive training. present narrative review provides concise, updated overview more recent evidence prevalence, profile, mechanisms, treatment people MS. should screened regular basis as part routine clinical assessments, brief tools now widely available (such Symbol Digit Modalities Test). main goal assessment prompt implementation preventive interventions.
Язык: Английский
Процитировано
37
Biological Psychiatry, Год журнала: 2023, Номер 95(12), С. 1072 - 1080
Опубликована: Ноя. 18, 2023
Multiple sclerosis (MS) is an immune-mediated neurological disorder, and up to 50% of patients experience depression. We investigated how white matter network disruption related depression in MS.
Язык: Английский
Процитировано
17
Neuroimaging Clinics of North America, Год журнала: 2024, Номер 34(3), С. 375 - 384
Опубликована: Апрель 25, 2024
Язык: Английский
Процитировано
9
Biomedical Signal Processing and Control, Год журнала: 2024, Номер 91, С. 105916 - 105916
Опубликована: Янв. 13, 2024
Язык: Английский
Процитировано
8